First data from the Trimer 4571 HIV vaccine trial on humans

Specialists from the Clinical Centre of the National Institute in Maryland, USA, have revealed the preliminary results from a Phase I clinical trial of the Trimer 4571 HIV vaccine which uses aluminium hydroxide as an adjuvant. The results were published in The Lancet.

The trial involved 16 adult participants who were HIV negative, six of which were men and the other ten were women. All participants received three doses of Trimer 4571 - 500mg either subcutaneously or intramuscularly. 

Side effects of mild and moderated severity were recorded. The most common of which was redness and pain at the injection site (14 people), followed by muscle and joint paint (6 people).

Antibodies binding Trimer 4571 were found in all trial participants two weeks after receiving the last dose of the candidate vaccine.

It’s an exciting time for HIV vaccine research with Moderna testing several variants of HIV vaccine produced on its HIV mRNA platform - a new study was recently launched in South Africa of candidate vaccine mRNA-1644.